An Event-Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 6, 2012, Pages 631-639

  Gagne, Joshua J ^a   Walker, Alexander M ^b,c   Glynn, Robert J ^a,c   Rassen, Jeremy A ^a   Schneeweiss, Sebastian ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b World Health Information Science Consultants LLC   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Active surveillance; Medical product monitoring; Operating characteristics; Performance metrics; Prospective safety monitoring; Time to alerting

Indexed keywords

ACCURACY; ARTICLE; COST; ELECTRONIC MEDICAL RECORD; HUMAN; MEDICAL PRODUCT MONITORING; METRIC SYSTEM; MONITORING; OUTCOME ASSESSMENT; PERFORMANCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMPUTER SIMULATION; DATA MINING; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84862230912     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2347     Document Type: Article

References (16)

1. Walker AM. Looking back from the year 2000. Drug regulation in the United States. J Clin Res Drug Devel 1989; 3: 259-264.
2. Walker AM, Wise RP. Precautions for proactive surveillance. Pharmacoepidemiol Drug Saf 2002; 11: 17-20.
3. Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011; 20: 1-11.
4. Avorn J, Schneeweiss S. Managing drug-risk information--what to do with all those new numbers. N Engl J Med 2009; 361: 647-649.
5. Walker AM. Signal detection for vaccine side effects that have not been specified in advance. Pharmacoepidemiol Drug Saf 2010; 19: 311-317.
6. Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf 2011; 20: 292-299.
7. Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA 2010; 304: 2019-2027.
8. Observational Medical Outcome Partnership. Challenge 2: Identifying drug-condition associations as data accumulates over time. . [Accessed on 2010 Jan 1].
9. Schneeweiss S. A basic study design for expedited safety signal refutation/confirmation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-868.
10. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004; 29: 2622-2631.
11. Hedner T, Samuelsson O, Lunde H, Lindholm L, Andrén L, Wiholm BE. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1992; 304: 941-946.
12. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-35.
13. van Rijsbergen CJ. Information retrieval (2nd edn). London: Butterworth-Heineman, 1979.
14. Matthews BW. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 1975; 405: 442-451.
15. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
16. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Sequential Analysis 2011; 30: 58-78.